News and Perspective

The phase 3 VESALIUS-CV trial demonstrates that adding evolocumab to standard lipid-lowering therapy significantly reduces the risk of a first major adverse cardiovascular event (MACE) in high-risk patients without prior myocardial infarction (MI) or stroke, establishing its benefit across the cardiovascular disease continuum.